QURE
uniQure N.V.
September 29, 2026 · pre-market
- Rarity
- 14.71
- Peak move
- −70.38%
- Float cap
- $2.2B
uniQure N.V. is a gene therapy company developing single treatments with potentially curative results for patients with rare and other devastating diseases. It is advancing clinical candidates for Huntington’s disease, refractory mesial temporal lobe epilepsy, Fabry disease, and amyotrophic lateral sclerosis caused by SOD1 mutations. These investigational therapies are intended for patients with serious, rare conditions and are not yet approved for commercial sale.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
1 event · 1 from SEC or newswire · 1 timed with the move- Timed with the move
clinical_readoutuniQure reported additional Phase I/II data for AMT-130 in Huntington's disease: in 12 high-dose patients at 48 months, cUHDRS showed 44% slowing of progression (p=0.144) and TFC 61% slowing (nominal p=0.008).
wireglobenewswire.comSEC8-K 0001104659-26-111654